HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury.
Lefer
D J
DJ
Department of Molecular and Cellular Physiology, LSU Health Sciences Center, Shreveport, Louisiana 71130, USA. dlefer@lsuhsc.edu
Scalia
R
R
Jones
S P
SP
Sharp
B R
BR
Hoffmeyer
M R
MR
Farvid
A R
AR
Gibson
M F
MF
Lefer
A M
AM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004730:Endothelium, Vascular / Q000201:enzymology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008954:Models, Biological; D017202:Myocardial Ischemia / Q000150:complications*; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000209:etiology; D009336:Necrosis; D009504:Neutrophils / Q000187:drug effects; D017942:Nitric Acid / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D012333:RNA, Messenger / Q000032:analysis; D019821:Simvastatin / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D012333:RNA, Messenger; D017942:Nitric Acid; D019821:Simvastatin; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III